Literature DB >> 25266803

RNA interference-mediated knockdown of RhoGDI2 induces the migration and invasion of human lung cancer A549 cells via activating the PI3K/Akt pathway.

Huiyan Niu1, Baogang Wu, Yang Peng, Hongfang Jiang, Yi Zhang, Jiahe Wang, Yifei Zhang, Ping He.   

Abstract

Rho GDP dissociation inhibitor 2 (RhoGDI2) has been identified as a tumor suppressor gene for cellular migration and invasion. However, the underlying mechanism and effector targets of RhoGDI2 in lung cancer are still not fully understood. In this study, a vector-expressed small hairpin RNA (shRNA) of RhoGDI2 was transfected into the human lung cancer cell line A549. After the successful transfection, the down-regulation of RhoGDI2 promoted the proliferation, migration, and invasion of lung cancer cells in vitro through the increasing expression and activities of the matrix metallopeptidase 9 (MMP-9) and PI3K/Akt pathways. Transiently transfecting the small interfering RNA (siRNA) of MMP-9 into the RhoGDI2 shRNA cells reduced the MMP-9 expression. Both transfecting the siRNA and adding the MMP-9 antibody into the RhoGDI2 shRNA cells led to a decrease in the invasion and migration of the lung cancer cells. The blockade of the PI3K/Akt pathway by LY294002 resulted in abolishment of the effects of RhoGDI2 shRNA in Akt phosphorylation and MMP-9 expression. This result suggests that the down-regulated RhoGDI2 contributed to the migration and invasion of the lung cancer cell line via activating the PI3K/Akt pathway and the ensuing increase in the expression and activity of MMP-9. In conclusion, we report that the shRNA-mediated knockdown of RhoGDI2 induces the invasion and migration of lung cancer due to cross-talk with the PI3K/Akt pathway and MMP-9. Verifying the role and molecular mechanism of the participation of RhoGDI2 in the migration and invasion of lung cancer may provide a target for better treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25266803     DOI: 10.1007/s13277-014-2671-9

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  32 in total

Review 1.  GDIs: central regulatory molecules in Rho GTPase activation.

Authors:  Céline DerMardirossian; Gary M Bokoch
Journal:  Trends Cell Biol       Date:  2005-07       Impact factor: 20.808

2.  Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells.

Authors:  A K Nalla; B Gorantla; C S Gondi; S S Lakka; J S Rao
Journal:  Cancer Gene Ther       Date:  2010-05-07       Impact factor: 5.987

Review 3.  Matrix metalloproteinases and tumor metastasis.

Authors:  Elena I Deryugina; James P Quigley
Journal:  Cancer Metastasis Rev       Date:  2006-03       Impact factor: 9.264

4.  Expression profile of RhoGDI2 in lung cancers and role of RhoGDI2 in lung cancer metastasis.

Authors:  Huiyan Niu; Hui Li; Can Xu; Ping He
Journal:  Oncol Rep       Date:  2010-08       Impact factor: 3.906

Review 5.  Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology.

Authors:  F R Hirsch; W A Franklin; A F Gazdar; P A Bunn
Journal:  Clin Cancer Res       Date:  2001-01       Impact factor: 12.531

Review 6.  Diverse mechanisms of AKT pathway activation in human malignancy.

Authors:  Mitchell Cheung; Joseph R Testa
Journal:  Curr Cancer Drug Targets       Date:  2013-03       Impact factor: 3.428

7.  Matrix metalloproteinases (MMPs) in bladder cancer: the induction of MMP9 by epidermal growth factor and its detection in urine.

Authors:  J E Nutt; G C Durkan; J K Mellon; J Lunec
Journal:  BJU Int       Date:  2003-01       Impact factor: 5.588

8.  Notch2 regulates matrix metallopeptidase 9 via PI3K/AKT signaling in human gastric carcinoma cell MKN-45.

Authors:  Ling-Yun Guo; Yu-Min Li; Liang Qiao; Tao Liu; Yuan-Yuan Du; Jun-Qiang Zhang; Wen-Ting He; Yong-Xun Zhao; Dong-Qiang He
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

9.  Loss of expression of LyGDI (ARHGDIB), a rho GDP-dissociation inhibitor, in Hodgkin lymphoma.

Authors:  Liya Ma; Gaixiang Xu; Anna Sotnikova; Monika Szczepanowski; Maciej Giefing; Kristina Krause; Matthias Krams; Reiner Siebert; Jie Jin; Wolfram Klapper
Journal:  Br J Haematol       Date:  2007-10       Impact factor: 6.998

10.  DLK1 promotes lung cancer cell invasion through upregulation of MMP9 expression depending on Notch signaling.

Authors:  Lin Li; Jinjing Tan; Ying Zhang; Naijun Han; Xuebing Di; Ting Xiao; Shujun Cheng; Yanning Gao; Yu Liu
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

View more
  10 in total

1.  XIAP overexpression promotes bladder cancer invasion in vitro and lung metastasis in vivo via enhancing nucleolin-mediated Rho-GDIβ mRNA stability.

Authors:  Yonghui Yu; Honglei Jin; Jiheng Xu; Jiayan Gu; Xin Li; Qipeng Xie; Haishan Huang; Jingxia Li; Zhongxian Tian; Guosong Jiang; Caiyi Chen; Feng He; Xue-Ru Wu; Chuanshu Huang
Journal:  Int J Cancer       Date:  2017-12-28       Impact factor: 7.396

2.  RhoGDIβ promotes Sp1/MMP-2 expression and bladder cancer invasion through perturbing miR-200c-targeted JNK2 protein translation.

Authors:  Haishan Huang; Honglei Jin; Huirong Zhao; Jingjing Wang; Xin Li; Huiying Yan; Shuai Wang; Xirui Guo; Lei Xue; Jingxia Li; Minggang Peng; Annette Wang; Junlan Zhu; Xue-Ru Wu; Changyan Chen; Chuanshu Huang
Journal:  Mol Oncol       Date:  2017-09-11       Impact factor: 6.603

3.  Increased dermal collagen bundle alignment in systemic sclerosis is associated with a cell migration signature and role of Arhgdib in directed fibroblast migration on aligned ECMs.

Authors:  Lizhi Cao; Robert Lafyatis; Linda C Burkly
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

4.  B7-H3 Promotes the Migration and Invasion of Human Bladder Cancer Cells via the PI3K/Akt/STAT3 Signaling Pathway.

Authors:  Yuchao Li; Guoning Guo; Jie Song; Zhiping Cai; Jin Yang; Zhiwen Chen; Yun Wang; Yaqin Huang; Qiangguo Gao
Journal:  J Cancer       Date:  2017-02-25       Impact factor: 4.207

5.  Identification of a Blood-Based Protein Biomarker Panel for Lung Cancer Detection.

Authors:  Victoria El-Khoury; Anna Schritz; Sang-Yoon Kim; Antoine Lesur; Katriina Sertamo; François Bernardin; Konstantinos Petritis; Patrick Pirrotte; Cheryl Selinsky; Jeffrey R Whiteaker; Haizhen Zhang; Jacob J Kennedy; Chenwei Lin; Lik Wee Lee; Ping Yan; Nhan L Tran; Landon J Inge; Khaled Chalabi; Georges Decker; Rolf Bjerkvig; Amanda G Paulovich; Guy Berchem; Yeoun Jin Kim
Journal:  Cancers (Basel)       Date:  2020-06-19       Impact factor: 6.639

6.  CRIF1 deficiency suppresses endothelial cell migration via upregulation of RhoGDI2.

Authors:  Harsha Nagar; Seonhee Kim; Ikjun Lee; Su-Jeong Choi; Shuyu Piao; Byeong Hwa Jeon; Minho Shong; Cuk-Seong Kim
Journal:  PLoS One       Date:  2021-08-26       Impact factor: 3.240

7.  Application of two-dimensional difference gel electrophoresis to identify protein changes between center, margin, and adjacent non-tumor tissues obtained from non-small-cell lung cancer with adenocarcinoma or squamous cell carcinoma subtype.

Authors:  Andrzej Ciereszko; Mariola A Dietrich; Mariola Słowińska; Joanna Nynca; Michał Ciborowski; Monika M Kaczmarek; Kamil Myszczyński; Joanna Kiśluk; Anna Majewska; Anna Michalska-Falkowska; Natalia Kodzik; Joanna Reszeć; Ewa Sierko; Jacek Nikliński
Journal:  PLoS One       Date:  2022-05-05       Impact factor: 3.752

8.  Down-regulation of HOXB5 inhibits TGF-β-induced migration and invasion in hepatocellular carcinoma cells via inactivation of the PI3K/Akt pathway.

Authors:  Jin-Ping Sun; Quan-Xing Ge; Zheng Ren; Xin-Fang Sun; Shu-Ping Xie
Journal:  RSC Adv       Date:  2018-12-11       Impact factor: 4.036

9.  FHL1 Overexpression as A Inhibitor of Lung Cancer Cell Invasion via Increasing RhoGDIß mRNA Expression.

Authors:  Min-Ke Shi; Yu-Long Xuan; Xiao-Feng He
Journal:  Cell J       Date:  2022-04-27       Impact factor: 3.128

Review 10.  B7-H3/CD276: An Emerging Cancer Immunotherapy.

Authors:  Wu-Tong Zhou; Wei-Lin Jin
Journal:  Front Immunol       Date:  2021-07-19       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.